Revr

The core of Tierra's business is its proprietary cell-free protein synthesis platform. This technology allows for the rapid, high-throughput production of custom proteins without the need for living cells, significantly accelerating research and development timelines. The platform operates on a 'protein-as-a-service' model, functioning through an e-commerce-like interface where clients can order specific proteins. This simplifies a traditionally complex and time-consuming process, making custom protein synthesis more accessible to a broader range of scientists and researchers.

Tierra's primary clients are scientists and R&D teams within pharmaceutical companies, agricultural technology firms, and other bio-based industries. By providing a streamlined method for creating and testing novel proteins, the company enables these clients to expedite the discovery and development of new drugs, sustainable materials, and agricultural products. For instance, the platform allows for the rapid screening of hundreds of protein variants to identify candidates with desired properties, a task that would be resource-intensive using conventional cell-based methods. Revenue is generated directly from these protein synthesis services. In 2021, the company secured $11 million in a Series A funding round, a milestone that has supported the expansion of its platform and team.